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Laboratory robotics has been firmly established in many non-QC
laboratories as a valuable tool for automating pharmaceutical
dosageform analysis. Often a single project or product line is used
to justify an initial robot purchase thus intr.oducing robotics to the
laboratoryfor thefirst time. However, to gain widespread acceptance
within the laboratory and to justifyfurther investment in robotics,
existing robots must be used to develop analysesfor existing manual
methods as well as new projects beyond the scope off the original
purchase justfcation. The Automation Development Group in
Analytical Research and Development is a team of analysts
primarily devoted to developing new methods and adapting existing
methodsfor the robot. This team approach developed the expertise
and synergy necessary to significantly expand the contribution 9f
robotics to automation in the authors’ laboratory.
Introduction
This paper will discuss how a small to mid-sized
pharmaceutical company is successfully using automation
during the early 1990s, a period of considerable and
fast-paced change.
research environment. In today’s business climate, R & D
costs must be not only contained but reduced. Project
timelines are getting tighter; a few years ago analysts
might have a year to develop methods and acquire and
validate data. Now they must do that same work in at
most six to nine months, with no compromise in quality.
Especially in pharmaceutical R & D, there are frequent
staff reorganizations which further limit the ongoing
support of individuals and management for robotics,
automation and new technologies in general. Automation
is no longer a ’sacred cow’; it must earn its keep just like
everything else in the budget by contributing to the
bottom line through increases in sample throughput and
productivity. Since robots have the potential to displace
or change certain job functions, especially where routine
sample preparation is concerned, enthusiasm among
laboratory workers for robots may be severely limited in a
downsizing’ environment where everybody worries about
job security. In a regulated industry like pharmaceuticals,
it is necessary to constantly improve the quality and
amount of the data supplied to the FDA, and with the
advent of the Clinton health plan we will need to further
improve cycle times if development costs are to be cut
and the organization to prosper in a new era of drug cost
containment.
The role of robotics
It is difficult to overemphasize how much things have
changed in the research and development environment
during the last 10 to !5 years. During the late 1970s and
early 1980s, many research organizations experienced
significant growth in their budgets for both personnel and
equipment. In the areas of automation and computers,
it was relatively easy to justify the purchase of new
equipment if one suggested that this would help
’automate’ or ’computerize’ an application or function.
During that same period a number ofindustries, including
petroleum and pharmaceuticals, were enjoying a rapid
increase in profits which made purchasing new equipment
easier. This scenario often leads to the anecdote about the
researcher who orders an expensive piece of equipment,
only to leave it packed in its original box to be tripped
over and eventually discarded by his replacement when
the original owner is promoted or retires.
The research environment is different today. This paper
will discuss the role of robotics in a pharmaceutical
development organization in the midst of a changing
This paper was presented at the 1993 ISLAR, organized by the
Zymark Corporation.
About two years ago it was decided to bring robotics into
Analytical Research and Development at DuPont Merck.
Since it is relatively new company and the analytical
section was mid-sized (less than 100 people) it could not
support a specialized department nor could it justify the
purchase of a lot of equipment. Instead robotics had to
improve productivity within the constraints of the
laboratory environment.
The department was responsible for developing methods
and specifications for bulk drugs, dosage forms and
reference standards as well as testing stability and release
samples and providing fbr the transfer of method and
technology to production sites in anticipation of NDA
approval. Based on this it seemed that robotics could make
the greatest impact if it could assist in the Phase II and
Phase III project development.
By the time a pharmaceutical company decides to take a
drug candidate into costly Phase II/III clinical trials, it
has already taken a big financial gamble that it will
succeed. However, even at this stage many drugs fail to
show efficacy or show undesirable side-effects. Depending
on the size of the clinical study, several dozen lots of
various strengths, packaging and tablet shapes may be on
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stability. Stability data is not only used to establish shelf
life of the various packages under different conditions
(which will eventually be used in the NDA submission
and in the market label) but to ensure that the various
tablets which are being given to patients in the clinic
meet the specifications for potency and purity. It is
vitally important that samples are analysed promptly
and correctly the first time to protect patients and to
alert the company to possible stability and storage
problems. Since samples are pulled at various intervals
specified in the stability protocol for each lot, only a
small time window is allowed for each analysis and its
reporting. All of these factors combine for high visibility
for analysts who decided to provide automated analyses
to assist in these projects.
Initial successes
During 1992 a Zymark Tablet Processing Workstation
(TPW) was installed. In conjunction with the Regulatory
Compliance Department and Metrologist the authors
developed and carried out the validation plan, wrote and
instituted metrology operating procedures, and budgeted
for the training of three operators. Due to this effort over
500 sample preparations were performed during a
three-month period with the TPW operators performing
the HPLC analysis as well. As the original project moved
toward the end ofPhase III, a secondTPW was purchased
and installed to handle the workload anticipated as the
drug moved into production and in support of other
phase II/III projects. However, just as the automation
effort was moving into high gear, the project was
cancelled!
Early lessons
In order to be knowledgeable about robotics, the authors
learned about the technology. It is not enough to learn
the basic operation for the TPW, for example it is vital
to have expertise in troubleshooting, maintenance, and
customizing. The authors developed partnerships with the
vendor, the scientists who developed the manual methods,
and with internal or external consultants.
One aspect that has deservedly received attention in
several recent papers has been the importance ofrecruiting
and developing the right staff to work with robotics. Not
everyone is able to be successful in this field. People who
develop and troubleshoot methods must be extremely
patient but persistent. They must pay great attention to
detail but still be able to see each component ofthe analysis
as a small part of the whole. They must also be skilled
analysts and have good people skills since they have to
interact with many laboratory personnel who may not
appreciate or understand what we do.
Major challenges
To be successful, the authors had to overcome a number
ofmajor challenges. There was a phase II project waiting
to be automated but there only was a short time--four
months--in which to develop and validate the methods
and issue all the required documentation. There was a
wide range of strengths, and since our TPW was not
equipped to do analytical dilutions, this presented a
problem. There was also evidence that the solvent in the
manual method caused foaming when the tablets were
homogenized and that the proposed internal standard was
unstable in solution. In addition, a new operator had to
be trained.
This project presented another major challenge which was
to the authors’ advantage: the management had decided
to concurrently develop a combinaton tablet as well as the
single entity. Because of the similarity in products, the
authors were able to use the solvent system already
developed for the combination tablet manual method for
both single entity and combination product automated
methods. This suggestion was made by the new
operator/analyst!
The purpose of this chronology is to illustrate the
environment that the automation group worked in.
Synergy is extremely important in an automation group.
Analysts must be able to work independently but they
must also communicate fully with each other and with
their customers in the laboratory. There is often not
enough time to develop elegant and totally novel
approaches to problems. By sharing information, and
using it effectively, thejob gets done on time and everyone
’owns’ the problem and the solution.
During 1993, in support of this project, over 400 sample
preparations were performed, and three automated
methods, a validation plan and report were issued and
included as alternate methods in the CMC filing. This
further increases our visibility and credibility. The
combination product methods were issued in October
1993. However, the project chemists felt that the internal
standard we were using took too long to elute. So, at their
request the authors developed and validated alternate
automated methods using external standard calibration.
These were issued soon after the other methods, and the
first samples were analysed the week before ISLAR 93.
Path forward
With both robots busy and two of the phase III projects
automated, the initial goals were met. In order to grow,
the first goal was to continue to educate the department,
management, and regulatory and documentation depart-
ments about the group’s work. The authors also needed
to continue training and developing their staff; this
meant allocating funds to send them to basic and
advanced Zymark training and to allow them the time
to take on new tasks that would challenge them and allow
them to master new skills. It was important to continue
to build synergy within the group, within the department
and with robotics users in other departments and sites
throughout the company. There was the ongoing
responsibility of managing the technology. Since both
robots had been used for over a year, maintenance and
troubleshooting became very important ifwe were to rely
on them for consistent performance. Parts and supplies
needed to be stocked and organized. Large quantities of
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reagents also needed to be stocked and stored. In addition,
the authors began to work with our industrial hygiene
department to monitor and limit analysts’ exposure to
solvents used in these analyses, as well as the noise
generated by the robots. In some cases this meant making
modifications to the rooms. Finally, special spill-control
procedures were written and equipment ordered to
minimize danger to staff and damage to equipment if any
of the systems should malfunction during unattended
operation. To shorten cycle times and improve quality of
analyses it is necessary to constantly upgrade equipment
and improve procedures, whether this is as simple as
reteaching a rack position, relocating a station or working
with building engineers to improve the performance of
hoods or the chilled water system.
Technology and new applications
For the longer term development of robotics in the
authors’ department there are two things that are
important: keeping abreast ofnew technology and finding
new niches or applications for robotics. Keeping abreast
of new technology may be as simple as inviting a vendor
in to demonstrate a new robot or autosampler. During
1992, the group had the opportunity to evaluate a
non-Zymark workstation during a three-week period.
During that time each member of our group was able to
learn the rudiments of the system and prepare several
samples. This experience will enable the group to
comment intelligently on this vendor’s product. Keeping
abreast of new technology also means purchasing robots
that have new or different features that may be helpful
in project development. These new products may open
up new applications for robotics in the lab as well as
improving the automation of current ones.
The authors have found that developing new niches for
robotics is a neverending task and one that is full of
surprises as well. A current project challenge is to develop
a robotic method for the preparation and analysis of a
combination drug that is contained in a multi-layer tablet.
It is a perfect application for a robot because the manual
method uses large amounts of chloroform and involves a
lot of repetitive motion. Using a robot can reduce the
chloroform exposure and the amount ofhuman repetitive
motion. The relatively short solution stability of the
product can be minimized by using the robot to prepare
each sample immediately before injection. In fact, this
will allow the assay for degradation products to be
combined with the potency assay, saving a separate
sample preparation and analysis for each sample.
However, there are many challenges: the multilayer tablet
is difficult to dissolve, the high rpms required for
homogenization represent a noise hazard. The chloroform
fumes must be contained and vented, and, finally, one of
the compounds is water sensitive. To deal with these
problems a Lucite containment hood has been built, which
is vented to the roof scrubbers. This serves to contain the
chloroform, as well as acting as a sound barrier. However,
there have been problems with additional chloroform
dripping from the wash line into the Fleaker during
homogenization, causing dilution of the sample. In this
case, the path of the tubing has been modified and a check
valve added. This is a good example of how investing
in new technology can help the robotics effort in
unanticipated ways--the purchase was originally justified
for making direct injections after sample preparation.
However, several features of the robot--its smaller size,
the option of using multiple solvents to wash the Fleaker
rather than just water and its unique probe and Fleaker
design have also helped method development in ways that
were not originally foreseen.
Conclusion
There are two lessons we have learned t?om our robotics
group that we feel are valuable for any laboratory
contemplating using robotics in an analytical research and
development lab. First, as with any new technique, the
more experience you have the better you become at using
robotics and finding new applications. Finally, the method
development process is cyclical. You return to the same
issue and challenges better equipped to deal with them
as well as the new challenges not previously encountered.
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